Tag: biology

Microcarriers Market Advances Due to Demand in Biologics Development

The global microcarriers market size was estimated at USD 1,945.7 million in 2024 and is projected to reach USD 3,500.8 million by 2030, growing at a CAGR of 10.5% from 2025 to 2030. This market growth is primarily attributed to the high demand for cell-based vaccines and therapeutics.

The increasing incidence of diseases such as diabetes, cancer, rheumatoid arthritis, and hemophilia, alongside significant investments in innovative therapy development and advancements in cell biology research, is fueling market expansion. For example, in May 2024, Sartorius partnered with Sanofi to co-develop a platform that enhances downstream bioprocessing, potentially advancing microcarrier-based technologies for efficient biopharmaceutical production.

The growing demand for cell-based vaccines and therapeutics remains a central driver of the market. These products offer targeted and effective treatment options for diseases like cancer and infectious disorders. Microcarriers are integral to this process, as they provide a supportive surface for large-scale cell culture expansion—crucial for vaccine and therapeutic manufacturing.

As the global population continues to age and expand, the prevalence of chronic and infectious diseases also rises. This demographic shift further accelerates the demand for novel cell-based treatments that utilize microcarriers for scalable and efficient cell culture.

Large-scale investments from pharmaceutical companies, biotech firms, and research institutions are driving innovation in cell-based therapies. These investments aim to develop scalable solutions using microcarriers for applications such as vaccines, gene therapies, and regenerative medicine. For instance, Eppendorf has focused on microcarrier-based systems to boost production efficiency and scalability.

Moreover, continuous technological advancements in cell biology research are enhancing the capabilities of microcarrier systems. Innovations in cell culture methods, bioreactor technologies, imaging, and biomaterials have significantly improved our understanding of cellular behavior, allowing for greater reproducibility and efficiency in manufacturing.

Order a free sample PDF of the Microcarriers Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights:

  • Regionally, North America generated the highest revenue in 2024.
  • Country-wise, China is projected to record the highest CAGR from 2025 to 2030.
  • Segment-wise, microcarrier beads generated USD 1,374.2 million in revenue in 2024.
  • Consumables, especially microcarrier beads, are expected to be the fastest-growing segment through 2030.

Market Size & Forecast:

  • 2024 Market Size: USD 1,945.7 Million
  • 2030 Projected Market Size: USD 3,500.8 Million
  • CAGR (2025–2030): 10.5%
  • North America: Largest regional market in 2024

Key Microcarrier Company Insights:

The microcarriers market is witnessing strong momentum due to continuous innovation and the increasing application of advanced technologies in cell biology. The growing need for effective disease treatments has created numerous opportunities in the cell therapy space. New market entrants and existing players are launching advanced solutions to meet evolving demands. For instance, in September 2023, Thermo Fisher Scientific introduced Gibco CTS Detachable Dynabeads—a new technology designed to streamline cell therapy manufacturing in clinical and commercial settings. The entry of such technologies intensifies market competition and accelerates innovation across the industry.

Key Players in the Microcarriers Market:

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Danaher Corporation
  • Sartorius AG
  • Corning Incorporated
  • Eppendorf SE
  • Bio-Rad Laboratories, Inc.
  • HiMedia Laboratories Pvt. Ltd.
  • denovoMATRIX GmbH

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global microcarriers market is set for robust growth driven by rising healthcare needs, advancements in cell-based therapies, and strong R&D investments. With chronic and infectious diseases on the rise, and continuous technological progress, microcarriers are becoming indispensable in large-scale bioproduction. The competitive landscape is also intensifying as established players and new entrants alike strive to introduce efficient, scalable, and innovative solutions, positioning the microcarriers market as a key component of the future biotechnology ecosystem.

Gene Therapy Market Propelled by Innovation in Viral and Non-Viral Vectors

The global gene therapy market was valued at USD 5.54 billion in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 18.88% from 2024 to 2030. This growth is driven by several key factors, including the rising advancement in therapeutic technologies and gene delivery methods, as well as intensifying competition among major industry players aiming to commercialize their therapies. Biotechnology firms are actively pursuing mergers, acquisitions, collaborations, and strategic partnerships to build internal expertise and strengthen their product pipelines.

The COVID-19 pandemic had an adverse impact on market performance. The industry faced significant disruptions in supply chains, production capabilities, and logistics operations. For example, certain companies experienced prolonged delays in obtaining specific components and later encountered shortages in clinical trial supplies after one of their contract manufacturing partners was forced to cease operations.

Despite this, the market is expected to gain momentum in the coming years, supported by a strong development pipeline. Researchers are striving to bring gene therapy into routine clinical practice. Numerous academic institutions and research centers have an extensive range of products under development, which is projected to contribute to revenue growth throughout the forecast period. Notably, clinical trials for gene therapy surged following the FDA’s approval of the first gene therapy in 2017. According to the American Society of Gene & Cell Therapy (ASGCT), there are currently approximately 1,986 gene therapy-related products in development, including CAR T-cell therapies and other genetically engineered cell treatments.

In addition, evolving regulatory frameworks are expected to foster further growth. Several global regulatory agencies have implemented positive changes to facilitate the advancement of gene therapies. For instance, the FDA has expressed strong support for CAR-T cell technology. During Phase II and III clinical studies, regulators are showing increased flexibility in the traditional trial structure. The FDA anticipates approving between 10 and 20 new gene therapies annually by 2025.

Increased funding and investment in gene therapy is also projected to offer promising growth prospects for industry players. Many biopharmaceutical companies are channeling resources into the development of new products. For example, Ori Biotech secured over USD 100.0 million in Series B funding in January 2022 to launch an innovative platform for cell and gene therapy development, enabling a swift progression from pre-commercialization to full market entry.

Get a preview of the latest developments in the Global Gene Therapy Market! Download your FREE sample PDF today and explore key data and trends

Regional Overview
In 2023, North America led the global gene therapy market, capturing a revenue share of 18.95%. This dominance is expected to continue throughout the forecast period, both in terms of regulatory approvals and revenue generation. Strong investment in research and development by both established and emerging companies is anticipated to drive further market expansion in the region.

Leading Companies in the Gene Therapy Market:
The key players shaping the gene therapy landscape and holding significant market shares include:

  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche
  • Gilead Sciences, Inc.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Legend Biotech
  • BioMarin
  • uniQure N.V.
  • Merck & Co.
  • Sarepta Therapeutics, Inc.
  • Krystal Biotech, Inc.
  • CRISPR Therapeutics

Gather more insights about the market drivers, restrains and growth of the Gene Therapy Market

Targeted DNA RNA Sequencing Market Forecast: Anticipating Changes in Consumer Preferences

The global targeted DNA RNA sequencing market size is expected to reach USD 34.56 billion in 2030 and is projected to grow at a CAGR of 19.4% from 2024 to 2030. Targeted Sequencing has emerged as a key technology in life science research by enabling examination of a specific region of interest while keeping the seq. cost as well as the complexity of data under manageable limits.

This approach enhances sequencing depth by allowing the evaluation of specific coding regions within genes or specific genes, which are known to harbor mutations for disease pathogenesis. Several research projects have employed this technology to avoid wastage of information and extra cost and study only relevant genes. The number of such projects continues to grow, consequently driving the market.

Innovations to address the pitfalls of targeted enrichment methods are anticipated to enhance the usage rate of this technology throughout the forecast period. Moreover, with a decrease in seq-cost and improvement in informatics, targeted methods have become more accessible for use in clinical settings than ever.

Access the Targeted DNA RNA Sequencing Market Size, Share & Trends Analysis Report By Product (NGS), By Workflow (Pre-sequencing), By Application, By Technology, By Type, By End Use, And Segment Forecasts, 2024 – 2030

Targeted DNA RNA Sequencing Market Report Highlights

  • Rapid advancements in NGS and its ancillary protocols can be attributed to the growth of this segment.
  • Out of all the NGS-based targeted methods, exome-seq held the largest share.
  • This can be attributed to the fact that though it accounts for less than 2% of the genome, it contains 85% of the known disease-relevant variants.
  • Entire targeted approach is broken down into presequencing, sequence determination, and data analysis.
  • Being the most crucial step, sequencing accounted for the largest share.
  • This space has revolutionized various applications of life sciences, including human biomedical research, plant & animal sciences, drug discovery, and others.
  • Out of all, human biomedical research is estimated to be the largest application of this space due to its high usage in studying disease pathogenesis.
  • The targeted DNA/RNA sequencing market is bifurcated into DNA-seq and RNA-seq, based on the sample type.
  • DNA-sequencing has been estimated to generate higher revenue over its counterpart segment. This can be attributed to the presence of a wide range of products and kits for DNA-seq.
  • As per end use, academic research is estimated to be the largest segment owing to the increase in seq-based projects at universities and other academic centers.
  • North America held the largest share owing to the presence of effective regulations pertaining to approval of genetic tests and bioinformatics tools.
  • Moreover, the U.S. is observed to have the highest number of installed sequencers, which in turn, has contributed to the large share of the North America regional market.
  • Asia Pacific is expected to emerge as the fastest growing regional market.
  • Rise in genome-based projects coupled with constant GDP growth in Asian countries is expected to drive the Asia Pacific market.

Key Targeted DNA RNA Sequencing Company Insights

Some key companies in the global targeted DNA RNA sequencing market include Illumina, F. Hoffman La-Roche Ltd, QIAGEN, Bio-Rad Laboratories, and others. Vendors in the market are focusing on increasing their customer base to gain a competitive edge in the industry. Therefore, key players undertake several strategic initiatives, such as mergers, acquisitions, and partnerships with other major companies.

Illumina is among the world’s foremost makers of genomic equipment including DNA sequencing and microarray technology. Their products assist researchers and healthcare providers with information that can be used to diagnose diseases, develop individualized treatments, and progress various scientific disciplines related to genetics.

Roche is a leading healthcare company, dedicated to research and innovation in pharmaceutical and diagnostic products. They own leading clinical products in oncology, immunology, and diagnostic products for personalized medicine.

Order your free sample copy of “Targeted DNA RNA Sequencing Market Report 2024 – 2030, published by Grand View Research

Key Targeted DNA RNA Sequencing Companies:

The following are the leading companies in the targeted DNA RNA sequencing market. These companies collectively hold the largest market share and dictate industry trends.

  • Illumina
  • F. Hoffman-La Roche Ltd.
  • QIAGEN
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Oxford Nanopore Technologies
  • PierianDx
  • Genomatix GmbH
  • DNASTAR, Inc.
  • Perkin Elmer, Inc.

Recent Developments

  • In June 2024, Bio-Rad launched a new ddSEQ Single-Cell 3′ RNA-Seq Kit to support single-cell gene expression research. This kit enables researchers to affordably and rapidly analyze gene expression on the single-cell resolution. It is anticipated that this technology will help in the research of oncology, immunology, and more.
  • In May 2024, a new paper was published in Genomic Medicine highlighting global efforts to increase access to genome sequencing for diagnosing rare genetic disorders and focusing on its potential to improve diagnosis speed and reduce healthcare costs. The Medical Genome Initiative calls for broader insurance coverage, reduced administrative barriers, and increased clinician education to support the widespread adoption of genome sequencing.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone:-1-415-349-0058

Email: sales@grandviewresearch.com

Design a site like this with WordPress.com
Get started